BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $500
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains an Outperform rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $480 to $500.
May 31, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Evan Seigerman has maintained an Outperform rating on Vertex Pharmaceuticals and increased the price target from $480 to $500.
The increase in the price target from $480 to $500 and the maintained Outperform rating by BMO Capital is a positive signal for investors, indicating confidence in Vertex Pharmaceuticals' future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100